These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 12974257)

  • 1. [The first original Russian class-III antiarrhythmic nibentan].
    Glushkov RG; Golitsyn SP; Dorodnikova EV; Maĭkov EB; Mashkovskiĭ MD; Merkulova IN; Rozenshtraukh LV; Ruda MIa; Skachilova SIa; Chazov EI; Iuzhakov SD
    Vestn Ross Akad Med Nauk; 1998; (11):38-41. PubMed ID: 9889704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Electrophysiological effects and mechanisms of antiarrhythmic action of nibentan in patients with paroxysmal arrhythmias].
    Golitsin SP
    Kardiologiia; 2003; 43(4):64-73. PubMed ID: 12968607
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of the class III antiarrhythmic drug nibentan in vagotonic atrial fibrillation].
    Popova EP; Lyskovtsev VV; Kaverina NV
    Eksp Klin Farmakol; 2006; 69(1):24-7. PubMed ID: 16579055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial contractility after in vitro treatment with class III antiarrhythmic drug Nibentan.
    Latfullin IA; Gaifullina RF; Dzhordzhikiya RK; Nigmatullina RR
    Bull Exp Biol Med; 2006 Jan; 141(1):81-3. PubMed ID: 16929971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of the anti-arrhythmic activity of cardiocyclide and nibentan in hypersympathotonia and acute myocardial ischemia].
    Vititnova MB; Kryzhanovskiĭ SA; Kaverina NV
    Eksp Klin Farmakol; 2002; 65(2):24-6. PubMed ID: 12109286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel antiarrhythmic class III drug nibentan: from experimental studies to clinical practice].
    Rosenshtraukh LV; Ruda MIa; Golitsyn SP; Maĭkov EB
    Kardiologiia; 2003; 43(6):66-8. PubMed ID: 12974257
    [No Abstract]   [Full Text] [Related]  

  • 7. [Value of experimental and clinical methods on the effectiveness and side effect profile of anti-arrhythmia agents].
    Kuck KH
    Z Kardiol; 1992; 81 Suppl 4():151-5. PubMed ID: 1283932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug prevention and therapy of ventricular tachycardia].
    Burckhardt D; Hoffmann A
    Ther Umsch; 1992 Aug; 49(8):543-9. PubMed ID: 1519183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sudden cardiac death--possibilities and limits of drug therapy].
    Manz M; Lüderitz B
    Z Kardiol; 1992 May; 81(5):237-45. PubMed ID: 1621403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of new anti-arrhythmia drugs after the CAST (Cardiac Arrhythmia Suppression Trial) study].
    Meinertz T; Zehender M; Hohnloser SH
    Z Kardiol; 1992; 81 Suppl 4():145-9. PubMed ID: 1290291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-arrhythmic and cardiodepressive effects of anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1988; 77 Suppl 5():113-9. PubMed ID: 2464875
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.